89biologo.png
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
June 10, 2021 08:30 ET | 89bio, Inc.
SAN FRANCISCO, June 10, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021 16:05 ET | 89bio, Inc.
SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio to Present at Upcoming Investor Conferences
May 05, 2021 08:00 ET | 89bio, Inc.
SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH
April 05, 2021 08:00 ET | 89bio, Inc.
- Received written guidance from FDA related to trial design and agreement to use liquid formulation -- ENLIVEN trial to initiate as planned in 2Q21 - SAN FRANCISCO, April 05, 2021 (GLOBE...
89biologo.png
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 24, 2021 16:05 ET | 89bio, Inc.
- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 - - NASH histology cohort topline data expected by YE21 - - Phase 2 SHTG trial (ENTRIGUE) expected to report topline data in...
89biologo.png
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
March 20, 2021 11:00 ET | 89bio, Inc.
SAN FRANCISCO, March 20, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio to Present at the Oppenheimer 31st Annual Healthcare Conference
March 11, 2021 08:00 ET | 89bio, Inc.
SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio to Participate in the H.C. Wainwright Global Life Sciences Conference
March 03, 2021 08:00 ET | 89bio, Inc.
SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference
February 24, 2021 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference
February 18, 2021 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...